Author:
Heidbreder Anna,Kunz Dieter,Young Pitt,Benes Heike,Chalet Francois-Xavier,Vaillant Cedric,Kaskel Peter,Fietze Ingo,Schöbel Christoph
Abstract
AbstractPeople suffering from chronic insomnia are at an increased risk of physical and mental illness. The absenteeism rate for people with sleep disorders in Germany is more than twice as high as for people without. Therefore, appropriate diagnosis and treatment of sleep disorders is a considerable medical and social necessity.The aim of this prospectively planned analysis is to describe self-reported effects of insomnia in everyday life and the current medical treatment situation in Germany.Data from a demographically representative sample of adults from the German participants in the National Health and Wellness Survey 2020 (N = 10,034) were analysed. Information was collected from respondents who reported insomnia confirmed by a physician (n = 532). The severity of insomnia at the time of the interview was assessed using the Insomnia Severity Index. Health status and quality of life were assessed using EQ-5D and SF-36, and work productivity and work impairment using the Work Productivity and Activity Impact Questionnaire.The median duration of illness was 5 years. About 50% of the respondents reported moderate to severe insomnia. Around 70% of those affected had never taken a prescription medication for their insomnia, and most of them said that they had never been recommended a prescription medication by a physician to treat their sleep disorder. Their health status, self-reported morbidity and quality of life were impaired compared with the general population.People with insomnia have worse health than those without insomnia. A significant proportion of those affected are currently not offered prescription medication. Even if the reasons for this lack of care cannot be clearly determined based on self-reported information, the data indicate an inadequate and relevant care deficit for chronic insomnia in Germany.
Funder
Universitätsklinikum Essen
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM‑5, 5 edn. American Psychiatric Publishing, Washington, D.C.
2. Baglioni C, Spiegelhalder K, Lombardo C, Riemann D (2010) Sleep and emotions: a focus on insomnia. Sleep Med Rev 14(4):227–238
3. Benjamin SE, Exar EN, Gamaldo CE (2023) An Integrated Interdisciplinary sleep care model-the ultimate dream team. JAMA Neurol 80(6):541–542
4. Bschor T (2022) II. Substanzspezifische Fragen. Benzodiazepine und Benzodiazepinanaloga (Z-Substanzen). https://www.bundesaerztekammer.de/fileadmin/user_upload/BAEK/Themen/Public_Health/Leitfaden-Medikamentenabhaengigkeit_final-Internetfassung.pdf. Zugegriffen: 6. Juli 2023 (Leitfaden „Schädlicher Gebrauch und Abhängigkeit von Medikamenten“ Herausgegeben von der Bundesärztekammer in Zusammenarbeit mit der Arzneimittelkommission der deutschen Ärzteschaft 7–12)
5. Bundesinstitut für Arzneimittel und Medizinprodukte (2023) ICD Internationale statistische Klassifikation der Krankheiten und verwandter Gesundheitsprobleme. https://www.bfarm.de/DE/Kodiersysteme/Klassifikationen/ICD/_node.html. Zugegriffen: 4. Aug. 2023